Get the Stockscreener App
4.62
0.86%
-0.04
Kalaris Therapeutics Inc stock is traded at $4.62, with a volume of 351.75K.
It is down -0.86% in the last 24 hours and up +81.18% over the past month.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
See More
Previous Close:
$4.66
Open:
$4.55
24h Volume:
351.75K
Relative Volume:
1.50
Market Cap:
$86.41M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+13.24%
1M Performance:
+81.18%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$4.34
$4.85
1-Week Range:
$3.75
$7.26
52-Week Range:
$2.14
$12.50
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
Name
Kalaris Therapeutics Inc
Sector
Industry
Phone
650-249-2727
Address
628 MIDDLEFIELD ROAD, PALO ALTO
Compare KLRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
4.62 | 87.15M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Jul-23-25 | Resumed | Piper Sandler | Neutral |
| May-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-08-25 | Initiated | William Blair | Outperform |
Kalaris Therapeutics Inc Stock (KLRS) Latest News
Momentum divergence signals in Kalaris Therapeutics Inc. chartJuly 2025 Drop Watch & Expert Curated Trade Setup Alerts - Newser
Top chart patterns to watch in Kalaris Therapeutics Inc.Gap Down & Comprehensive Market Scan Insights - Newser
Using data models to predict Kalaris Therapeutics Inc. stock movementEarnings Trend Report & Weekly High Return Forecasts - Newser
What data driven models say about Kalaris Therapeutics Inc.’s future2025 Technical Overview & Advanced Technical Analysis Signals - Newser
Kalaris Therapeutics Inc. recovery potential after sell offIPO Watch & Free Fast Entry Momentum Trade Alerts - Newser
Can a trend reversal in Kalaris Therapeutics Inc. lead to recoveryWeekly Trading Summary & Weekly Setup with ROI Potential - Newser
Volatility clustering patterns for Kalaris Therapeutics Inc.Bond Market & Weekly Return Optimization Alerts - Newser
Does Kalaris Therapeutics Inc. fit your quant trading modelWeekly Stock Report & Free High Return Stock Watch Alerts - Newser
Using Bollinger Bands to evaluate Kalaris Therapeutics Inc.July 2025 Sentiment & Fast Gain Swing Trade Alerts - Newser
Kalaris Therapeutics Inc. stock trend outlook and recovery pathMarket Sentiment Report & Technical Pattern Alert System - Newser
Is Kalaris Therapeutics Inc. impacted by rising ratesMarket Volume Summary & Low Risk High Win Rate Stock Picks - خودرو بانک
Kalaris Therapeutics, Inc.Common Stock (Nasdaq:KLRS) Stock Quote - FinancialContent
Is Kalaris Therapeutics Inc. a good stock for dollar cost averagingMarket Sentiment Report & Short-Term Trading Alerts - خودرو بانک
Forecasting Kalaris Therapeutics Inc. price range with options dataWeekly Trade Summary & Weekly High Return Forecasts - Newser
What’s the recovery path for long term holders of Kalaris Therapeutics Inc.Quarterly Portfolio Report & Consistent Growth Stock Picks - Newser
Can Kalaris Therapeutics Inc. Overcome Bearish SentimentDividend Hike & Verified Technical Signals - beatles.ru
What earnings revisions data tells us about Kalaris Therapeutics Inc.Earnings Recap Report & Fast Entry Momentum Alerts - Newser
Will Kalaris Therapeutics Inc. bounce back from current supportQuarterly Trade Summary & Verified Short-Term Plans - Newser
Key metrics from Kalaris Therapeutics Inc.’s quarterly dataBuy Signal & Accurate Buy Signal Notifications - Newser
Can Kalaris Therapeutics Inc. stock outperform in a bear market2025 Trading Volume Trends & Safe Capital Investment Plans - خودرو بانک
What’s Kalaris Therapeutics Inc.’s historical return2025 Bull vs Bear & Expert Curated Trade Setups - خودرو بانک
How does Kalaris Therapeutics Inc. compare to its peersPortfolio Profit Report & Precise Entry and Exit Recommendations - خودرو بانک
Is Kalaris Therapeutics Inc. stock risky to hold now2025 Market Overview & Verified Chart Pattern Signals - خودرو بانک
Kalaris Eyes A Game-Changing Breakthrough In Anti-VEGF Therapy With TH103 To Treat retinal Disease - RTTNews
Using data filters to optimize entry into Kalaris Therapeutics Inc.Trade Risk Assessment & High Win Rate Trade Alerts - Newser
Kalaris (KLRS.O) Surges 13%—What's Driving the Intraday Move? - AInvest
Raymond James Initiates Coverage on Strong Buy, PT $23 with Kalaris - AInvest
Kalaris Therapeutics Peeks Ahead: Strong Cash Reserves Empower Vital Trials - StocksToTrade
Kalaris Therapeutics shares surge 32.38% intraday after Zacks and Raymond James upgrade ratings and merger completion. - AInvest
Is Kalaris Therapeutics Inc. stock reversal real or fake2025 Year in Review & Smart Money Movement Tracker - Newser
Chart overlay techniques for tracking Kalaris Therapeutics Inc.2025 Institutional Moves & Weekly Watchlist for Consistent Profits - Newser
Raymond James Initiates Kalaris Therapeutics at Strong Buy - MarketScreener
Recap Report: Is Kalaris Therapeutics Inc. stock risky to hold nowJuly 2025 Summary & AI Powered Market Entry Strategies - خودرو بانک
How sensitive is Kalaris Therapeutics Inc. to inflationWeekly Market Outlook & Free Community Consensus Stock Picks - خودرو بانک
Analyzing Kalaris Therapeutics Inc. with multi timeframe chartsIndex Update & Accurate Entry/Exit Alerts - Newser
Will Kalaris Therapeutics Inc. benefit from rising consumer demandWeekly Market Summary & Detailed Earnings Play Alerts - خودرو بانک
Kalaris Therapeutics Inc Stock (KLRS) Financials Data
There is no financial data for Kalaris Therapeutics Inc (KLRS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):